Population pharmacokinetic and pharmacodynamic modeling of pegvisomant in Asian and Western acromegaly patients

Journal of Clinical Pharmacology

Volumn 51, Issue 12, 2011, Pages 1628-1643

  Muto, Chieko ^a,b   Chiba, Koji ^b   Suwa, Toshio ^b  

^a PFIZER INC   (United States)

^b KEIO UNIVERSITY   (Japan)

Author keywords

acromegaly; growth hormone receptor antagonist; IGF I; Pegvisomant; population PK PD

Indexed keywords

GROWTH HORMONE; PEGVISOMANT; SOMATOMEDIN C;

ACROMEGALY; ADULT; AGED; ARTICLE; ASIAN; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE TITRATION; FEMALE; HUMAN; IC 50; JAPANESE; MAJOR CLINICAL STUDY; MALE; POPULATION DYNAMICS; PROTEIN BLOOD LEVEL; RACE DIFFERENCE; STEADY STATE;

ACROMEGALY; ADULT; AGE FACTORS; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GROWTH HORMONE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RECEPTORS, SOMATOTROPIN; YOUNG ADULT;

EID: 82955241456     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010386954     Document Type: Article

References (32)

1. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev. 2002 ; 23: 623-646 (Pubitemid 35191626)
2. Giustina A, Chanson P, Bronstein MD, et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010 ; 95: 3141-3148
3. Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009 ; 94: 1509-1517
4. Fuh G, Cunningham BC, Fukunaga R, Nagata S, Goeddel DV, Wells JA. Rational design of potent antagonists to the human growth hormone receptor. Science. 1992 ; 256: 1677-1680
5. Goffin V, Bernichtein S, Carriere O, Bennett WF, Kopchick JJ, Kelly PA. The human growth hormone antagonist B2036 does not interact with the prolactin receptor. Endocrinology. 1999 ; 140: 3853-3856 (Pubitemid 30645443)
6. Ross RJM, Leung KC, Maamra M, et al. Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. J Clin Endocrinol Metab. 2001 ; 86: 1716-1723 (Pubitemid 32374928)
7. Pradhananga S, Wilkinson I, Ross RJ. Pegvisomant: structure and function. J Mol Endocrinol. 2002 ; 29: 11-14 (Pubitemid 34965742)
8. Brabant G. Insulin-like growth factor-I: marker for diagnosis of acromegaly and monitoring the efficacy of treatment. Eur J Endocrinol. 2003 ; 148 (Suppl 2). S15-20
9. van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. The Lancet. 2001 ; 358: 1754-1759 (Pubitemid 33152999)
10. Kopchick JJ. Discovery and mechanism of action of pegvisomant. Eur J Endocrinol. 2003 ; 148 (Suppl 2). S21-25
11. Stewart PM. Pegvisomant: an advance in clinical efficacy in acromegaly. Eur J Endocrinol. 2003 ; 148 (Suppl 2). S27-32
12. Paisley AN, Trainer P, Drake W. Pegvisomant: a novel pharmacotherapy for the treatment of acromegaly. Expert Opinion on Biological Therapy. 2004 ; 4: 421-425 (Pubitemid 38352136)
13. Roelfsema F, Biermasz NR, Pereira AM, Romijn JA. The role of pegvisomant in the treatment of acromegaly. Expert Opin Biol Ther. 2008 ; 8: 691-704 (Pubitemid 351685032)
14. SOMAVERT pegvisomant for injection USPI, revised April 2008. http://media.pfizer.com/files/products/uspi-somavert.pdf. Accessed October 22, 2010.
15. SOMAVERT Summary of Product Characteristics, authorized September 2007 http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000409/WC500054629.pdf. Accessed October 22, 2010.
16. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000 ; 342: 1171-1177 (Pubitemid 30211048)
17. Pharmaceuticals and Medical Devices Agency, Approval Package Somavert (pegvisomant) injectable. Company: Pfizer http://www.info.pmda.go.jp/shinyaku/ g070108/40007900-21900AMY00004-W1051.pdf. Accessed October 22, 2010. (in Japanese).
18. US Food and Drug Administration Center for Drug Evaluation and Research, Approval Package Somavert (pegvisomant) injectable. Company: Pharmacia and Upjohn, Application No.: 021106 Approval Date: 3/25/2003. http://www.accessdata. fda.gov/drugsatfda-docs/nda/2003/021106-somavert.cfm. Accessed October 22, 2010.
19. Thorner MO, Strasburger CJ, Wu Z, et al. Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. J Clin Endocrinol Metab. 1999 ; 84: 2098-2103 (Pubitemid 30647040)
20. Yin D, Vreeland F, Schaaf LJ, Millham R, Duncan BA, Sharma A. Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy. Clin Cancer Res. 2007 ; 13: 1000-1009 (Pubitemid 46340379)
21. Jonsson EN, Karlsson MO. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1998 ; 58: 51-64 (Pubitemid 29049052)
22. Hashimoto Y, Odani A, Tanigawara Y, Yasuhara M, Okuno T, Hori R. Population analysis of the dose-dependent pharmacokinetics of zonisamide in epileptic patients. Biol Pharm Bull. 1994 ; 17: 323-326 (Pubitemid 24112358)
23. Odani A, Hashimoto Y, Takayanagi K, et al. Population pharmacokinetics of phenytoin in Japanese patients with epilepsy: analysis with a dose-dependent clearance model. Biol Pharm Bull. 1996 ; 19: 444-448 (Pubitemid 26098579)
24. Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther. 2007 ; 82: 17-20 (Pubitemid 46944205)
25. Parkinson C, Burman P, Messig M, Trainer PJ. Gender, body weight, disease Activity, and previous radiotherapy influence the response to pegvisomant. J Clin Endocrinol Metab. 2007 ; 92: 190-195 (Pubitemid 46067530)
26. Maamra M, Kopchick JJ, Strasburger CJ, Ross RJ. Pegvisomant, a growth hormone-specific antagonist, undergoes cellular internalization. J Clin Endocrinol Metab. 2004 ; 89: 4532-4537 (Pubitemid 39244465)
27. Veldhuis JD, Bidlingmaier M, Anderson SM, Evans WS, Wu Z, Strasburger CJ. Impact of experimental blockade of peripheral growth hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men. J Clin Endocrinol Metab. 2002 ; 87: 5737-5745 (Pubitemid 36034384)
28. Veldhuis JD, Bidlingmaier M, Anderson SM, Wu Z, Strasburger CJ. Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-Peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men. J Clin Endocrinol Metab. 2001 ; 86: 3304-3310 (Pubitemid 32673502)
29. Hilding A, Hall K, Wivall-Helleryd I-L, Sääf M, Melin AL, Thorén M. Serum levels of insulin-like growth factor I in 152 patients with growth hormone efficiency, aged 19-82 years, in relation to those in healthy subjects. J Clin Endocrinol Metab. 1999 ; 84: 2013-2019 (Pubitemid 30647027)
30. Mauras N, O'Brien KO, Welch S, et al. Insulin-like growth factor I and growth hormone (GH) treatment in GH-deficient humans: differential effects on protein, glucose, lipid, and calcium metabolism. J Clin Endocrinol Metab. 2000 ; 85: 1686-1694 (Pubitemid 32289519)
31. Aimaretti G, Fanciulli G, Bellone S, et al. Enhancement of the peripheral sensitivity to growth hormone in adults with GH deficiency. Eur J Endocrinol. 2001 ; 145: 267-272 (Pubitemid 32825658)
32. Laursen T, Møller J, Fisker S, Jorgensen JO, Christiansen JS. Effects of a 7-day continuous infusion of octreotide on circulating levels of growth factors and binding proteins in growth hormone (GH)-treated GH-deficient patients. Growth Horm IGF Res. 1999 ; 9: 451-457 (Pubitemid 30069612)